Logo image
Back
Human C-peptide Dose Dependently Prevents Early Neuropathy in the BB/Wor-rat
Journal article   Open access

Human C-peptide Dose Dependently Prevents Early Neuropathy in the BB/Wor-rat

W. Zhang, M. Yorek, C. R. Pierson, Y. Murakawa, A. Breidenbach and A. A. F. Sima
International journal of experimental diabetes research, Vol.2(3), pp.187-193
2001
DOI: 10.1155/EDR.2001.187
PMCID: PMC2478548
PMID: 12369706
url
https://doi.org/10.1155/EDR.2001.187View
Published (Version of record) Open Access

Abstract

In order to explore the neuroprotective and crossspecies activities of.C-peptide on type 1 diabetic neuropathy, spontaneously diabetic BB/W-rats were given increasing doses of human recombinant Cpeptide (hrC-peptide). Diabetic rats received 10, 100, 500, or 1000 μg of hrC-peptide/kg body weight/ day from onset of diabetes. After 2 months of hrC-peptide administration, 100 μg and greater doses completely prevented the nerve conduction defect, which was associated with a significant but incomplete prevention of neural Na + / K + -ATPase activity in diabetic rats with 500 μg or greater C-peptide replacement. Increasing doses of hrC-peptide showed increasing prevention of early structural abnormalities such as paranodal swelling and axonal degeneration and an increasing frequency of regenerating sural nerve fibers. We conclude that hrC-peptide exerts a dose dependent protection on type 1 diabetic neuropathy in rats and that this effect is probably mediated by the partially conserved sequence of the active C-terminal pentapeptide

Details

Metrics

21 Record Views
Logo image